Condition
XSCID
Total Trials
3
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
P 1 (1)
Trial Status
Enrolling By Invitation2
Unknown1
Clinical Trials (3)
Showing 3 of 3 trials
NCT06851767Phase 1Enrolling By Invitation
Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene Therapy
NCT01346150Unknown
Patients Treated for SCID (1968-Present)
NCT01186913Enrolling By Invitation
Natural History Study of SCID Disorders
Showing all 3 trials